Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 906349, 10 pages
http://dx.doi.org/10.1155/2015/906349
Clinical Study

The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)

1Translational Development, Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901, USA
2Biostatistics, Celgene Corporation, 33 Technology Drive, Warren, NJ 07059, USA

Received 26 September 2014; Accepted 10 January 2015

Academic Editor: Marco Antonio Velasco-Velázquez

Copyright © 2015 Peter H. Schafer et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [35 citations]

The following is the list of published articles that have cited the current article.

  • Irina V. Medvedeva, Matthew E. Stokes, Dominic Eisinger, Samuel T. LaBrie, Jing Ai, Matthew W. B. Trotter, Peter Schafer, and Robert Yang. View at Publisher · View at Google Scholar
  • Emma D. Deeks, “Apremilast: A Review in Psoriasis and Psoriatic Arthritis,” Drugs, 2015. View at Publisher · View at Google Scholar
  • Alejandro Souto, and Juan J Gómez-Reino, “Apremilast for the treatment of psoriatic arthritis,” Expert Review of Clinical Immunology, pp. 1–10, 2015. View at Publisher · View at Google Scholar
  • Frederic Liote, Federico Diaz-Gonzalez, Maurizio Cutolo, Chiachi Hu, Randall M. Stevens, Airi Poder, Gary E. Myerson, Roy M. Fleischmann, Filip Van Den Bosch, Helena Marzo-Ortega, Eugen Feist, and Kamal Shah, “A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial,” Journal of Rheumatology, vol. 43, no. 9, pp. 1724–1734, 2016. View at Publisher · View at Google Scholar
  • M. Heng, “Protein kinases and phophodiesterases in psoriasis: time to refocus on biochemistry,” British Journal of Dermatology, vol. 175, no. 3, pp. 455–456, 2016. View at Publisher · View at Google Scholar
  • Luca Bianchi, Ester Del Duca, Marco Romanelli, Rosita Saraceno, Sergio Chimenti, and Andrea Chiricozzi, “Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis,” Expert Opinion on Drug Metabolism & Toxicology, pp. 1–8, 2016. View at Publisher · View at Google Scholar
  • Yong Liu, Simon Zhou, Mahmoud Assaf, Jim Nissel, and Maria Palmisano, “Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12,” Clinical Pharmacology in Drug Development, vol. 5, no. 6, pp. 469–479, 2016. View at Publisher · View at Google Scholar
  • Francesco Caso, Antonio Del Puente, Rosario Peluso, Paolo Caso, Nicolò Girolimetto, Aurora Del Puente, Raffaele Scarpa, and Luisa Costa, “Emerging drugs for psoriatic arthritis,” Expert Opinion on Emerging Drugs, pp. 1–11, 2016. View at Publisher · View at Google Scholar
  • Melodie Young, and Heather L. Roebuck, “Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease,” Journal of the American Association of Nurse Practitioners, 2016. View at Publisher · View at Google Scholar
  • Wang Sin Gina Tan, Stephen Kelly, and Costantino Pitzalis, “Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis,” Expert Review of Clinical Immunology, pp. 1–16, 2016. View at Publisher · View at Google Scholar
  • Luisa Costa, Antonio Del Puente, Rosario Peluso, Marco Tasso, Paolo Caso, Maria Sole Chimenti, Vincenzo Sabbatino, Nicolò Girolimetto, Carolina Benigno, Nicoletta Bertolini, Aurora Del Puente, Roberto Perricone, Raffaele Scarpa, and Francesco Caso, “Small molecule therapy for managing moderate to severe psoriatic arthritis,” Expert Opinion on Pharmacotherapy, pp. 1–11, 2017. View at Publisher · View at Google Scholar
  • Lazaros I. Sakkas, Athanasios Mavropoulos, and Dimitrios P. Bogdanos, “Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of action, clinical applications, current and future perspectives,” Current Medicinal Chemistry, vol. 24, no. 28, pp. 3054–3067, 2017. View at Publisher · View at Google Scholar
  • Angela McArdle, Stephen Pennington, and Oliver FitzGerald, “Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs,” Clinical Reviews in Allergy & Immunology, 2017. View at Publisher · View at Google Scholar
  • Marco Spadaccini, Silvia D?Alessio, Laurent Peyrin-Biroulet, and Silvio Danese, “PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue,” International Journal of Molecular Sciences, vol. 18, no. 6, pp. 1276, 2017. View at Publisher · View at Google Scholar
  • Stephanie Oehrl, Hridayesh Prakash, Annette Ebling, Nina Trenkler, Priscila Wölbing, Anja Kunze, Thomas Döbel, Marc Schmitz, Alexander Enk, and Knut Schäkel, “The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells,” Journal of Dermatological Science, 2017. View at Publisher · View at Google Scholar
  • Gillian M. Keating, “Apremilast: A Review in Psoriasis and Psoriatic Arthritis,” Drugs, 2017. View at Publisher · View at Google Scholar
  • Abigail Cline, Leah A. Cardwell, and Steven R. Feldman, “Advances in treating psoriasis in the elderly with small molecule inhibitors,” Expert Opinion on Pharmacotherapy, pp. 1–9, 2017. View at Publisher · View at Google Scholar
  • Hanns-Martin Lorenz, Karolina Benesova, and Niko Kai Bender, “Novel Therapeutic Strategies in Inflammatory Joint Diseases,” Aktuelle Rheumatologie, 2017. View at Publisher · View at Google Scholar
  • I. Vujic, R. Herman, M. Sanlorenzo, C. Posch, B. Monshi, K. Rappersberger, and L. Richter, “Apremilast in psoriasis - a prospective real-world study,” Journal of the European Academy of Dermatology and Venereology, 2017. View at Publisher · View at Google Scholar
  • Jerry Thomas, and Sharon E. Jacob, “Apremilast,” Journal of the Dermatology Nurses’ Association, vol. 9, no. 3, pp. 154–156, 2017. View at Publisher · View at Google Scholar
  • Richard Kast, “Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment,” Medical Sciences, vol. 6, no. 4, pp. 84, 2018. View at Publisher · View at Google Scholar
  • Scott A. Elman, Michael E. Weinblatt, and Joseph F. Merola, “Targeted therapies for psoriatic arthritis: An update for the dermatologist,” Seminars in Cutaneous Medicine and Surgery, vol. 37, no. 3, pp. 173–181, 2018. View at Publisher · View at Google Scholar
  • Sandra Garcet, Kristine Nograles, Joel Correa da Rosa, Peter H. Schafer, and James G. Krueger, “Synergistic cytokine effects as apremilast response predictors in patients with psoriasis,” Journal of Allergy and Clinical Immunology, 2018. View at Publisher · View at Google Scholar
  • Emma Guttman‐Yassky, Jon M. Hanifin, Mark Boguniewicz, Andreas Wollenberg, Robert Bissonnette, Vivek Purohit, Iain Kilty, Anna M. Tallman, and Michael A. Zielinski, “The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition,” Experimental Dermatology, 2018. View at Publisher · View at Google Scholar
  • Martina Biggioggero, Chiara Crotti, Andrea Becciolini, Elisabetta Miserocchi, and Ennio Giulio Favalli, “The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future,” BioMed Research International, vol. 2018, pp. 1–11, 2018. View at Publisher · View at Google Scholar
  • Julie Kieffer, Florence Le Duff, Henri Montaudié, Christine Chiaverini, Jean-Philippe Lacour, and Thierry Passeron, “Treatment of Severe Hailey-Hailey Disease With Apremilast,” JAMA Dermatology, 2018. View at Publisher · View at Google Scholar
  • Adam Reich, Agnieszka Osmola-Mankowska, Agnieszka Owczarczyk-Saczonek, Waldemar Placek, Jacek Szepietowski, Zygmunt Adamski, Grazyna Chodorowska, Andrzej Kaszuba, Aleksandra Lesiak, Joanna Maj, Witold Owczarek, Lidia Rudnicka, Dorota Krasowska, and Joanna Narbutt, “Psoriasis. Diagnostic and therapeutic recommendations of the polish dermatological society. Part II: Moderate to severe psoriasis,” Przeglad Dermatologiczny, vol. 105, no. 3, pp. 329–357, 2018. View at Publisher · View at Google Scholar
  • Bruce Strober, Ali Alikhan, Benjamin Lockshin, Rebecca Shi, Joshua Cirulli, and Peter Schafer, “Apremilast Mechanism of Efficacy in Systemic-Naive Patients With Moderate Plaque Psoriasis: Pharmacodynamic Results From the UNVEIL Study,” Journal of Dermatological Science, 2019. View at Publisher · View at Google Scholar
  • Robert Bissonnette, Ana B. Pavel, Aisleen Diaz, John L. Werth, Chuanbo Zang, Ivana Vranic, Vivek S. Purohit, Michael A. Zielinski, Bonnie Vlahos, Yeriel D. Estrada, Etienne Saint-Cyr Proulx, William C. Ports, and Emma Guttman-Yassky, “Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial,” Journal of Allergy and Clinical Immunology, 2019. View at Publisher · View at Google Scholar
  • Afroditi Boulougoura, Erin Gabriel, Elizabeth Laidlaw, Vikram Khetani, Ken Arakawa, Jeanette Higgins, Adam Rupert, Robert J Gorelick, Keith Lumbard, Alice Pau, April Poole, Angela Kibiy, Princy Kumar, and Irini Sereti, “A Phase I, Randomized, Controlled Clinical Study of CC-11050 in People Living With HIV With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE),” Open Forum Infectious Diseases, vol. 6, no. 6, 2019. View at Publisher · View at Google Scholar
  • Athanasios Mavropoulos, Efterpi Zafiriou, Theodora Simopoulou, Alexandros G Brotis, Christos Liaskos, Aggeliki Roussaki-Schulze, Christina G Katsiari, Dimitrios P Bogdanos, and Lazaros I Sakkas, “Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis,” Rheumatology, 2019. View at Publisher · View at Google Scholar
  • Emily Baumrin, Abby Van Voorhees, Amit Garg, Steven R. Feldman, and Joseph F. Merola, “A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation,” Journal of the American Academy of Dermatology, 2019. View at Publisher · View at Google Scholar
  • Tue W. Kragstrup, Mary Adams, Søren Lomholt, Morten A. Nielsen, Line D. Heftdal, Peter Schafer, and Bent Deleuran, “ IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis ,” Therapeutic Advances in Musculoskeletal Disease, vol. 11, pp. 1759720X1982866, 2019. View at Publisher · View at Google Scholar
  • Sarah M Wade, Mary Canavan, Trudy McGarry, Candice Low, Siobhan C Wade, Ronan H Mullan, Douglas J Veale, and Ursula Fearon, “Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis,” Annals of the Rheumatic Diseases, vol. 78, no. 3, pp. 350–354, 2019. View at Publisher · View at Google Scholar
  • Geetha Krishnamoorthy, Aditya Kotecha, and Jason Pimentel, “Complete resolution of erythrodermic psoriasis with first-line apremilast monotherapy,” BMJ Case Reports, vol. 12, no. 1, pp. e226959, 2019. View at Publisher · View at Google Scholar